These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27514838)

  • 21. BRCA testing is important for our patients.
    Anderson BO; Javid SH; Calhoun KE; Byrd DR
    Surgery; 2012 Apr; 151(4):637-8. PubMed ID: 22306834
    [No Abstract]   [Full Text] [Related]  

  • 22. BRCA in breast cancer: ESMO Clinical Practice Guidelines.
    Balmaña J; Diez O; Rubio I; Castiglione M;
    Ann Oncol; 2010 May; 21 Suppl 5():v20-2. PubMed ID: 20555082
    [No Abstract]   [Full Text] [Related]  

  • 23. A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes.
    Nomizu T; Matsuzaki M; Katagata N; Kobayashi Y; Sakuma T; Monma T; Saito M; Watanabe F; Midorikawa S; Yamaguchi Y
    Breast Cancer; 2015 Sep; 22(5):557-61. PubMed ID: 23242612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic Testing After Previous BRCA Testing: A Case Study.
    Ward M
    Clin J Oncol Nurs; 2016 Dec; 20(6):660-663. PubMed ID: 27857264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
    Levy-Lahad E; Lahad A; King MC
    J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
    [No Abstract]   [Full Text] [Related]  

  • 26. BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision.
    Coakley M; Cleary V; Power N; O'Reilly S
    Eur J Hum Genet; 2017 Feb; 25(2):167-168. PubMed ID: 27759028
    [No Abstract]   [Full Text] [Related]  

  • 27. Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.
    Manahan ER; Kuerer HM; Sebastian M; Hughes KS; Boughey JC; Euhus DM; Boolbol SK; Taylor WA
    Ann Surg Oncol; 2019 Oct; 26(10):3025-3031. PubMed ID: 31342359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.
    Wu H; Wu X; Liang Z
    Gene Ther; 2017 Oct; 24(10):601-609. PubMed ID: 28771233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline Genetic Testing: What the Breast Surgeon Needs to Know.
    Plichta JK; Sebastian ML; Smith LA; Menendez CS; Johnson AT; Bays SM; Euhus DM; Clifford EJ; Jalali M; Kurtzman SH; Taylor WA; Hughes KS
    Ann Surg Oncol; 2019 Jul; 26(7):2184-2190. PubMed ID: 30941656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic testing in women with breast cancer: implications for treatment.
    Paterson R; Phillips KA
    Expert Rev Anticancer Ther; 2017 Nov; 17(11):991-1002. PubMed ID: 28853307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2.
    Kaldate R; Huston A; McCoy H; Cardeiro D; Noyes K
    Breast J; 2014; 20(3):325-6. PubMed ID: 24708220
    [No Abstract]   [Full Text] [Related]  

  • 33. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
    Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
    BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic testing for BRCA1 and BRCA2 in the Province of Ontario.
    Finch A; Wang M; Fine A; Atri L; Khalouei S; Pupavac M; Rosen B; Eisen A; Elser C; Charames G; Metcalfe K; Chang MC; Narod SA; Lerner-Ellis J
    Clin Genet; 2016 Mar; 89(3):304-11. PubMed ID: 26219728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Armstrong K; Weber BL
    Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
    [No Abstract]   [Full Text] [Related]  

  • 37. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
    Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
    Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
    Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the effectiveness of NICE criteria for stratifying breast cancer risk in a UK cohort.
    Littlejohn LA; Gibbs J; Jordan LB; Miedzybrodzka ZH; Bell C; Goudie D; Dunlop J; Berg JN
    Eur J Hum Genet; 2018 Apr; 26(4):599-603. PubMed ID: 29335492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
    Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
    J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.